Facebook
Instagram
Pinterest
Reddit
Tumblr
X
Youtube
Home
About
News
Events
Shop
Directory
Contact Us
Search
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Password recovery
Recover your password
your email
A password will be e-mailed to you.
PsyNews.com
Home
About
News
Events
Shop
Directory
Contact Us
Home
Featured
Page 194
Featured
Latest
Latest
Featured posts
Most popular
7 days popular
By review score
Random
After the Readout: How the Field Is Interpreting Compass’ Phase 3 Psilocybin Data
Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts
Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast
BREAKING: Second Positive Phase 3 for Compass’ Psilocybin, Though Modest Magnitude Raises Questions
AtaiBeckley Seeks Partner for BPL-003 as Pharma Interest Builds After AbbVie-Gilgamesh Deal
Psyched Wellness Announces Launch of New Logo, Branding, and Website, Prepares...
Numinus Appoints New Bioscience Advisors to Advance IP Development
PharmaTher Granted FDA Orphan Drug Designation for Ketamine to Treat Status...
Mydecine Submits Pre-Investigational New Drug Briefing Package to the FDA for...
Psychedelic or Not: Of Mice, 5-HT2A Agonists, and Head Shakes
PT289 – Payton Nyquvest – Shifting the Mindset on Pain, Psychedelics,...
Psychedelic Bulletin: MDMA Fast-Tracked in UK; FDA Clears MindMed LSD Trial;...
Red Light Holland’s Partner CCrest Laboratories Approved By Health Canada to...
PT288 – Annie & Michael Mithoefer – Vital Psychedelic Conversations
Numinus Identified as a Licensed Psilocybin Supplier by Health Canada
Load more